AUS
NZ
UK
CA
USA
IND
Healthcare
Highlights of Abbott's Q3 are being outlined
October 15, 2024 03:31 AM PDT| By Team Kalkine MediaHighlights:,Abbott is projected to report Q3 2024 revenue of $10.6 billion and adjusted earnings of $1.20 per share, aligning with market expectations.,Growth is anticipated across multiple segments, particularly driven by increased sales of the Free...
Innovative liposomal drug delivery platform by Lipella Pharmaceuticals has received U.S. patent allowance
October 15, 2024 02:29 AM PDT| By Team Kalkine MediaHighlights:,Lipella Pharmaceuticals has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform.,The patent, titled 'Delivery of Agents Using Metastable Liposomes,...
Important developments in cancer treatment are being undertaken by IQ-AI
October 15, 2024 02:07 AM PDT| By Team Kalkine MediaHighlights:,IQ-AI Ltd is nearing completion of its Phase I clinical trial for IB003, a gallium maltolate therapy targeting children's brain cancer, with only two patients remaining for enrollment.,The company is preparing for a critical meeting with...
Cycle Pharmaceuticals Pushes for Vanda Acquisition Amid Struggles
October 14, 2024 03:18 PM PDT| By Team Kalkine MediaHighlights,Cycle Pharmaceuticals has reaffirmed its acquisition proposal for Vanda Pharmaceuticals, offering an all-cash deal that significantly values Vanda above its recent stock price, with the aim of expanding its presence in the pharmaceutical s...
NAYA Biosciences Emerges from INVO Merger with Expanded Focus
October 14, 2024 03:15 PM PDT| By Team Kalkine MediaHighlights,INVO Bioscience has successfully merged with NAYA Biosciences, forming a new entity that combines INVO's fertility business with NAYA's advancements in oncology and autoimmune disease therapies, operating under the name NAYA Biosciences.,T...
Integer Holdings Surges to New High Following Analyst Praise
October 14, 2024 01:25 PM PDT| By Team Kalkine MediaHeadlines,Integer Holdings achieves a new 1-year high after favorable analyst upgrades,Positive ratings from multiple analysts boost market confidence,Strong trading volume indicates heightened investor interest,Integer Holdings Co.,(NYSE:ITGR),has r...
Stryker's Growth Potential Highlighted by Analysts' Price Target Increases
October 14, 2024 12:37 PM PDT| By Team Kalkine MediaHeadlines,Stryker's Target Price Raised by Truist Financial,Multiple Analysts Weigh In on Stryker,Stryker Continues to Gain Attention from Analysts,Stryker,(NYSE:SYK),recently received a price target increase from research analysts at Truist Financia...
Owlet Regains NYSE Compliance: A Step Toward Financial Stability
October 14, 2024 08:45 AM PDT| By Team Kalkine MediaHeadlines,Owlet regains compliance with NYSE listing standards.,The company no longer faces compliance issues after meeting NYSE requirements.,Owlet enters a 12-month monitoring period for continued compliance.,Owlet,,(NYSE:OWLT),a company specializi...
AxoGen Shares Surge Amid Positive Sentiment
October 14, 2024 07:43 AM PDT| By Team Kalkine MediaHighlights,AxoGen's shares soared significantly in the last trading session, driven by positive market sentiment and increased trading volume, reflecting growing investor interest in the Healthcare sector.,The Federal Reserve's aggressive rate cut ha...
What Led to Bio-Rad Laboratories Shareholders Facing Losses Over the Past Three Years?
October 14, 2024 05:12 AM PDT| By Team Kalkine MediaHighlights:,Bio-Rad Laboratories, Inc.,(NYSE:BIO),operates in the healthcare and life sciences sector.,The stock experienced a decrease in value over the past three years.,The company's share price saw a decline in line with broader market trends.,Bi...
How Has Danaher Grown Over the Last Five Years?
October 14, 2024 05:08 AM PDT| By Team Kalkine MediaHighlights,Danaher Corporation operates within the medical and industrial equipment sectors.,The stock has experienced consistent long-term growth, particularly in the past five years.,Danaher’s market performance reflects its presence in various cri...
Phase III Study of Nasal Polyps Treatment Celebrated by GSK
October 14, 2024 05:03 AM PDT| By Team Kalkine MediaHighlights:,GSK PLC reports positive outcomes from two pivotal clinical trials (ANCHOR-1 and ANCHOR-2) evaluating depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP).,Participants receiving depemokimab demonstrated significant reduction...
Jasper Therapeutics Shares Encouraging Data from SPOTLIGHT Study on Briquilimab for Chronic Inducible Urticaria
October 14, 2024 04:23 AM PDT| By Team Kalkine MediaHighlights:,Jasper Therapeutics announced promising results from its SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab for chronic inducible urticaria (CIndU).,A clinical response was observed in 93% of participants within six weeks, with 83% o...
Why Is Royalty Pharma Maintaining Its Dividend?
October 14, 2024 04:15 AM PDT| By Team Kalkine MediaHighlights,Royalty Pharma plc is set to distribute a dividend on December 10th.,The dividend amount is $0.21 per share.,The company's dividend yield stands above the industry average.,Royalty Pharma plc,(NASDAQ:RPRX),operates within the healthcare an...
BARDA Funding Secured by RedHill Biopharma to Enhance Opaganib Development for Ebola Treatment
October 14, 2024 04:14 AM PDT| By Team Kalkine MediaHighlights:,RedHill Biopharma has secured funding from BARDA to advance the development of opaganib as a treatment for Ebola virus disease (EBOV).,Recent studies funded by the U.S. Army demonstrated that opaganib significantly improved survival rates...
Bicycle Therapeutics (BCYC) Climbs 5.7%: Further Upside Evaluated
October 14, 2024 03:55 AM PDT| By Team Kalkine MediaHighlights:,Bicycle Therapeutics PLC (BCYC) shares rose 5.7% to close at $26.46, supported by significantly increased trading volume.,The company's lead drug, zelenectide pevedotin, is currently undergoing evaluation in the phase II/III Duravelo-2 st...
Strategic Deal Between Lundbeck and Longboard Pharmaceuticals Aims to Enrich Neuroscience Pipeline
October 14, 2024 03:34 AM PDT| By Team Kalkine MediaHighlights:,Lundbeck has announced the acquisition of Longboard Pharmaceuticals to strengthen its neuroscience pipeline, valued at approximately USD 2.6 billion.,The deal will integrate the innovative product bexicaserin, currently in late-stage deve...
Why Did Nurix Therapeutics Exceed Profit Targets Amid Lower Revenue?
October 14, 2024 03:18 AM PDT| By Team Kalkine MediaHighlights:,Nurix Therapeutics focuses on targeted protein modulation therapies.,Q3 GAAP earnings per share (EPS) showed a reduction, but outperformed expectations.,The company reported a decrease in revenue compared to the previous year.,Nurix Thera...
Innate Pharma's Executive Board Welcomes Jonathan Dickinson as New CEO
October 14, 2024 03:00 AM PDT| By Team Kalkine MediaHighlights:,Innate Pharma has appointed Jonathan Dickinson as its new Chief Executive Officer and Chairman of the Executive Board, effective November 1, 2024.,Dickinson brings a wealth of experience from senior leadership roles at prominent biotech a...
PacBio Partners with National Cancer Centre Singapore for Cancer Research
October 11, 2024 03:19 PM PDT| By Team Kalkine MediaHighlights,PacBio and the National Cancer Centre of Singapore (NCCS) have entered a research collaboration aimed at advancing cancer research using cutting-edge sequencing technologies.,The collaboration will combine PacBio's Onso short-read and Kinn...
